ORIC Pharmaceuticals, Inc. · Healthcare · Biotechnology
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$13.45
−$0.05 (−0.41%) 4:00 PM ET
After hours$13.50
+$0.05 (+0.41%) 5:24 PM ET
Prev closePrevC$13.50
OpenOpen$13.12
Day highHigh$13.73
Day lowLow$13.04
VolumeVol794,961
Avg volAvgVol1,597,594
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$1.31B
P/E ratio
-9.02
EPS
-1.49
Sector
Healthcare
AI report sections
BULLISH
ORIC
ORIC Pharmaceuticals, Inc.
No AI report section text found yet for this symbol.
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff
The precision oncology market is projected to grow from $110 billion to $225.65 billion by 2032, driven by Big Pharma's race to acquire registration-ready assets ahead of a $170 billion patent cliff through 2030. Several biotech companies are advancing promising clinical programs: Oncolytics Biotech strengthened its leadership team for pelareorep development in gastrointestinal cancers; Nurix is executing pivotal studies for its BTK degrader bexobrutideg in chronic lymphocytic leukemia; Erasca reported early clinical data for its pan-RAS molecular glue ERAS-0015; Foghorn raised $50 million for its SMARCA4-targeting program; and ORIC presented strong Phase 1b data for rinzimetostat in prostate cancer.
Reported strong Phase 1b data for rinzimetostat in prostate cancer (55% PSA50 response rate, 59% ctDNA clearance) and enozertinib in lung cancer (67% ORR), with plans to initiate Phase 3 registrational trial in H1 2026 and extended cash runway to H2 2028.
PositiveGlobeNewswire Inc.• Oric Pharmaceuticals
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025
ORIC Pharmaceuticals presented promising Phase 1b trial results for enozertinib, demonstrating strong systemic and CNS activity in NSCLC patients with EGFR exon 20 mutations, with high objective response rates and a competitive safety profile.
ORICenozertinibNSCLCEGFRclinical trialoncology
Sentiment note
Presented strong preliminary clinical trial data showing high objective response rates (67% in 1L, 45% in 2L), 100% intracranial response in some patient groups, manageable safety profile, and potential best-in-class positioning for their drug enozertinib
PositiveGlobeNewswire Inc.• Oric Pharmaceuticals
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025
ORIC Pharmaceuticals presented promising Phase 1b trial results for enozertinib, a potential treatment for non-small cell lung cancer (NSCLC) with EGFR mutations, showing strong systemic and CNS activity with favorable safety profile.
Demonstrated strong preliminary results with 80% overall response rate in first-line NSCLC patients, 100% intracranial response rate, and no significant off-target toxicities, indicating promising drug development progress
PositiveGlobeNewswire Inc.• Oric Pharmaceuticals
ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor
ORIC Pharmaceuticals published research in Cancer Research detailing enozertinib, a highly selective brain-penetrant EGFR inhibitor targeting non-small cell lung cancer mutations, demonstrating potential for treating intracranial disease.
ORICenozertinibEGFRlung cancerbrain metastasescancer research
Sentiment note
Company published promising preclinical data showing a novel drug's potential to address unmet medical needs in cancer treatment, with a patient case demonstrating complete response in systemic and brain metastases
PositiveGlobeNewswire Inc.• Oric Pharmaceuticals, Inc.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals, Inc. announced the grant of 39,100 non-qualified stock options and 6,500 restricted stock units to three new non-executive employees. The grants were made as inducements to employment in accordance with Nasdaq rules.
The article announces that ORIC Pharmaceuticals granted stock options and restricted stock units to new employees, indicating the company is expanding and providing incentives to attract talent.
PositiveGlobeNewswire Inc.• Oric Pharmaceuticals, Inc.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals, a clinical-stage oncology company, announced that it granted stock options and restricted stock units to two new non-executive employees as inducement awards. The grants were made under the company's 2022 Inducement Equity Incentive Plan.
ORICORIC Pharmaceuticalsinducement equity awardsstock optionsrestricted stock units
Sentiment note
The article announces that ORIC Pharmaceuticals granted inducement equity awards to new employees, which is a positive sign for the company's growth and ability to attract talent.
PositiveBenzinga• Prnewswire
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year
The article discusses the promising developments in cancer research, including new therapies and innovative technologies, and highlights recent updates from several biotech companies working on cutting-edge cancer treatments.
ONCYADPTNEOELEVcanceroncologybiotechimmunotherapy
Sentiment note
The article highlights ORIC Pharmaceuticals' progress in 2024, including the initiation of multiple cohorts for its drug candidates ORIC-114 and ORIC-944, as well as its strategic collaborations and strong cash position, positioning the company for continued progress in oncology drug development.
PositiveGlobeNewswire Inc.• Oric Pharmaceuticals, Inc.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals, a clinical-stage oncology company, announced granting stock options and restricted stock units to a new non-executive employee as an inducement to employment. The grants were made under the company's 2022 Inducement Equity Incentive Plan.
ORICORIC Pharmaceuticalsinducement equity awardsstock optionsrestricted stock units
Sentiment note
The article announces that ORIC Pharmaceuticals granted inducement equity awards to a new employee, which is a positive sign of the company's growth and ability to attract talent.
NeutralGlobeNewswire Inc.• N/A
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
C4 Therapeutics, Inc. (C4T) has appointed Steve Hoerter, a veteran with over three decades of experience in oncology commercialization, to its Board of Directors. Hoerter's expertise in strategically advancing oncology programs is expected to guide C4T's plans to become a fully integrated biotechnology company.
CCCCAGIOORICC4 TherapeuticsSteve HoerteroncologycommercializationBoard of Directors
Sentiment note
The article mentions that Hoerter is on the Board of Directors of ORIC Pharmaceuticals, a clinical-stage oncology company, but does not provide any additional details about this role or the company's performance.
PositiveGlobeNewswire Inc.• Oric Pharmaceuticals, Inc.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals, a clinical-stage oncology company, announced granting stock options and restricted stock units to four new non-executive employees as inducement awards. The grants were made under the company's 2022 Inducement Equity Incentive Plan.
ORICORIC Pharmaceuticalsinducement equity awardsstock optionsrestricted stock units
Sentiment note
The article announces that ORIC Pharmaceuticals is granting inducement equity awards to new employees, which is a positive sign for the company's growth and ability to attract talent.
PositiveGlobeNewswire Inc.• Oric Pharmaceuticals, Inc.
ORIC Pharmaceuticals announced clinical collaborations with Bayer and Johnson & Johnson to evaluate ORIC-944, a PRC2 inhibitor, in combination with their respective AR inhibitors darolutamide and apalutamide for the treatment of metastatic prostate cancer.
The article highlights ORIC Pharmaceuticals' progress in advancing its clinical trials and entering into strategic collaborations to evaluate its lead product candidate ORIC-944 in combination with other therapies, which suggests a positive outlook for the company.
PositiveGlobeNewswire Inc.• Oric Pharmaceuticals, Inc.
ORIC Pharmaceuticals, a clinical-stage oncology company, announced granting stock options and restricted stock units to three new non-executive employees as inducement awards.
ORICORIC Pharmaceuticalsoncologyinducement equity awardsstock optionsrestricted stock units
Sentiment note
The article announces that ORIC Pharmaceuticals granted inducement equity awards to new employees, which suggests the company is actively expanding its workforce and investing in its future growth.
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
